Elevated S1P levels are also implicated in multiple cancers, including ovarian, prostate, colorectal, breast, and hepatocellular carcinoma [13], underscoring the potential of the S1P signaling pathway as a therapeutic target. This evidence concerns the gene MBTPS1 and cancer.